<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372499</url>
  </required_header>
  <id_info>
    <org_study_id>DM-PTHE</org_study_id>
    <nct_id>NCT03372499</nct_id>
  </id_info>
  <brief_title>Diet Management on Hepatic Encephalopathy of Patients With Variceal Bleeding After Intrahepatic Portosystemic Shunt Creation</brief_title>
  <acronym>DM-PTHE</acronym>
  <official_title>Effect of Diet Management on Incidence of Hepatic Encephalopathy of Patients With Cirrhosis and Variceal Bleeding After Transjugular Intrahepatic Portosystemic Shunt Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Li Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic encephalopathy is a severe complication of transjugular intrahepatic portosystemic
      shunt (TIPS) treatment in patients with cirrhosis and variceal bleeding. This study is
      specially designed to explore whether diet management strategy could decrease incidence of
      encephalopathy after TIPS treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic encephalopathy (HE) is a severe complication of TIPS treatment in patients with
      cirrhosis and variceal bleeding. The overall incidence of post-TIPS encephalopathy ranges
      between 10% and 50%, and even the percentage of the new or worsened HE was evaluated up to
      13-36%. No approach or medication was evidenced for prophylaxis of post-TIPS encephalopathy,
      including lactulose and rifaximin. Diet management has been used as an important part of the
      prophylaxis and treatment strategy for patients with metabolic diseases like diabetes and
      nephritis, which has drawn increasing interest of clinicians. Nevertheless, there is still no
      standard consensus or even recommendation for patients after TIPS procedure for now, which
      worsened malnutrition and affected survival. Thus, this study is specially designed to
      explore whether diet management strategy, drawn up from the nutritional management consensus
      of hepatic encephalopathy (ISHEN consensus), could decrease incidence of encephalopathy after
      TIPS treatment of the patient with cirrhosis and variceal bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Hepatic Encephalopathy</measure>
    <time_frame>1 year</time_frame>
    <description>incidence of symptomatic hepatic encephalopathy in all stages within 1 year after enrollment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver Transplantation-free Survival Rate</measure>
    <time_frame>1 year</time_frame>
    <description>survival rate free of liver transplantation within 1 year after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Stent Dysfunction</measure>
    <time_frame>1 year</time_frame>
    <description>Narrowing or even complete occlusion of the stent, evidenced by imaging examination and/or upper gastrointestinal endoscopy, with or without clinic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Portal Hypertension Related Severe Complications</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of severe complications of portal hypertension, especially for failure of control of acute variceal bleeding and clinical significant rebleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Nutritional Status</measure>
    <time_frame>1 year</time_frame>
    <description>Human body components analysis, evaluated by score of the Inbody Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Quality of Life</measure>
    <time_frame>1 year</time_frame>
    <description>Health related quality of life, assessed by score of the widely used questionaire Short Form 36.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>nutritional management group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>diet management strategy for encephalopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Current ordinary guidance for patients after TIPS placement performed by trained nurse in the inpatient department</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>diet management strategy for encephalopathy</intervention_name>
    <description>diet management strategy for encephalopathy means diet management strategy from the nutritional management consensus of hepatic encephalopathy.</description>
    <arm_group_label>nutritional management group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with decompensated liver cirrhosis regardless of the etiology

          -  acute variceal bleeding or with history of variceal bleeding evidenced by endoscopy

          -  an age between 18 and 75 years old

        Exclusion Criteria:

          -  a total bilirubin level more than 3mg/dL (51.3mmol/L)

          -  a creatinine level greater than 3 mg/dL(265umol/L)

          -  severe dysfunction of heart and respiratory system

          -  pregnancy

          -  uncontrolled neoplasm

          -  active systemic infection

          -  history of any kind of encephalopathy, mental disease, alcohol dependence, or any
             other status that influence brain function

          -  diabetes or any other metabolic diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Yang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Yang, MD</last_name>
    <phone>+86 18980601276</phone>
    <email>yangli_hx@scu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongjun Zhu, Doctor</last_name>
    <phone>+86 13281121937</phone>
    <email>hp545204493@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>+86</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yang, MD</last_name>
      <phone>+86 18980601276</phone>
      <email>yangli_hx@scu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yongjun Zhu, Doctor</last_name>
      <phone>+86 13281121937</phone>
      <email>hp545204493@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yongjun Zhu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>RÃ¶ssle M. TIPS: 25 years later. J Hepatol. 2013 Nov;59(5):1081-93. doi: 10.1016/j.jhep.2013.06.014. Epub 2013 Jun 25. Review.</citation>
    <PMID>23811307</PMID>
  </reference>
  <reference>
    <citation>Somberg KA, Riegler JL, LaBerge JM, Doherty-Simor MM, Bachetti P, Roberts JP, Lake JR. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunts: incidence and risk factors. Am J Gastroenterol. 1995 Apr;90(4):549-55.</citation>
    <PMID>7717309</PMID>
  </reference>
  <reference>
    <citation>Routhu M, Safka V, Routhu SK, Fejfar T, Jirkovsky V, Krajina A, Cermakova E, Hosak L, Hulek P. Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS). Ann Hepatol. 2017 Jan-Feb;16(1):140-148. doi: 10.5604/16652681.1226932.</citation>
    <PMID>28051803</PMID>
  </reference>
  <reference>
    <citation>Luo L, Fu S, Zhang Y, Wang J. Early diet intervention to reduce the incidence of hepatic encephalopathy in cirrhosis patients: post-Transjugular Intrahepatic Portosystemic Shunt (TIPS) findings. Asia Pac J Clin Nutr. 2016;25(3):497-503. doi: 10.6133/apjcn.092015.14.</citation>
    <PMID>27440683</PMID>
  </reference>
  <reference>
    <citation>Nardelli S, Gioia S, Pasquale C, Pentassuglio I, Farcomeni A, Merli M, Salvatori FM, Nikolli L, Torrisi S, Greco F, Nicoletti V, Riggio O. Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. Am J Gastroenterol. 2016 Apr;111(4):523-8. doi: 10.1038/ajg.2016.29. Epub 2016 Mar 1.</citation>
    <PMID>26925879</PMID>
  </reference>
  <reference>
    <citation>Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, Attili AF, Merli M. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008 Nov;103(11):2738-46. doi: 10.1111/j.1572-0241.2008.02102.x. Epub 2008 Sep 4.</citation>
    <PMID>18775022</PMID>
  </reference>
  <reference>
    <citation>Riggio O, Masini A, Efrati C, Nicolao F, Angeloni S, Salvatori FM, Bezzi M, Attili AF, Merli M. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005 May;42(5):674-9.</citation>
    <PMID>15826716</PMID>
  </reference>
  <reference>
    <citation>Riggio O, Ridola L, Angeloni S, Cerini F, Pasquale C, Attili AF, Fanelli F, Merli M, Salvatori FM. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. J Hepatol. 2010 Aug;53(2):267-72. doi: 10.1016/j.jhep.2010.02.033. Epub 2010 Apr 27.</citation>
    <PMID>20537753</PMID>
  </reference>
  <reference>
    <citation>Riggio O, Nardelli S, Moscucci F, Pasquale C, Ridola L, Merli M. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012 Feb;16(1):133-46. doi: 10.1016/j.cld.2011.12.008. Epub 2012 Jan 4. Review.</citation>
    <PMID>22321469</PMID>
  </reference>
  <reference>
    <citation>Yang Z, Han G, Wu Q, Ye X, Jin Z, Yin Z, Qi X, Bai M, Wu K, Fan D. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol. 2010 Nov;25(11):1718-25. doi: 10.1111/j.1440-1746.2010.06400.x.</citation>
    <PMID>21039832</PMID>
  </reference>
  <reference>
    <citation>Masson S, Mardini HA, Rose JD, Record CO. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience. QJM. 2008 Jun;101(6):493-501. doi: 10.1093/qjmed/hcn037. Epub 2008 Apr 25.</citation>
    <PMID>18440957</PMID>
  </reference>
  <reference>
    <citation>Suraweera D, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver. 2016 Jul 15;10(4):509-19. doi: 10.5009/gnl15419. Review.</citation>
    <PMID>27377741</PMID>
  </reference>
  <reference>
    <citation>Berlioux P, Robic MA, Poirson H, MÃ©tivier S, Otal P, Barret C, Lopez F, PÃ©ron JM, Vinel JP, Bureau C. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology. 2014 Feb;59(2):622-9.</citation>
    <PMID>24620380</PMID>
  </reference>
  <reference>
    <citation>Kramer L, Bauer E, Gendo A, Funk G, Madl C, Pidlich J, Gangl A. Neurophysiological evidence of cognitive impairment in patients without hepatic encephalopathy after transjugular intrahepatic portosystemic shunts. Am J Gastroenterol. 2002 Jan;97(1):162-6.</citation>
    <PMID>11808942</PMID>
  </reference>
  <reference>
    <citation>Abdelsayed GG. Diets in Encephalopathy. Clin Liver Dis. 2015 Aug;19(3):497-505. doi: 10.1016/j.cld.2015.05.001. Review.</citation>
    <PMID>26195204</PMID>
  </reference>
  <reference>
    <citation>Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010 Nov;32(9):1080-90. doi: 10.1111/j.1365-2036.2010.04448.x. Epub 2010 Sep 3.</citation>
    <PMID>20822500</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>December 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Li Yang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Hepatic Encephalopathy</keyword>
  <keyword>Diet Management</keyword>
  <keyword>Transjugular Intrahepatic Portosystemic Shunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The investigators need to discuss with other participants whether or not to share data of the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

